Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target

Benzinga Newsdesk www.benzinga.com Negative 85.8%

Neg 85.8% Neu 0% Pos 0%

Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and maintains $15 price target.